Programma

Targeted treatment for oncogene addicted NSCLC

The time of ‘one size fits all’ lies behind us. Platinum-doublet chemotherapy as first line therapy for all patients with advanced non-small-cell lung cancer (NSCLC), followed by second line docetaxel upon progression for fit patients is a treatment of the past.

Major progress has been made in diagnostics (from none up to next generation sequencing and whole exome or genome sequencing) and therapeutic management, resulting in personalized therapy for every lung cancer patient.

As the diagnostic and therapeutic management of NSCLC evolves, the treating physician (you) has to evolve in the same pace. A modern pulmonary oncologist needs to be a molecular biologist, chemotherapist, immunologist, tyrosine kinase inhibitorist and palliative specialist, combined in one person.

During this presentation, we will discuss the diagnostic work-up of patients with advanced stage NSCLC, the interpretation of genetic results (is this mutation targetable or not), the therapeutic options for oncogene driven NSCLC, the use of liquid and tissue biopsies to identify TKI resistance and strategies to overcome TKI resistance.